Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Tumor necrosis factor inhibitors
7 evidence topics · 5 sources
Recommendations for anti-TNF therapy: ACG 2025 guideline
Pivotal trial efficacy of infliximab, adalimumab, and golimumab: ACG 2025 guideline
Efficacy tiers by prior advanced-therapy exposure: AGA 2024 living guideline
“In patients who are naïve to advanced therapies, the AGA suggests using a higher efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab) or an intermediate efficacy medication (golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab), rather than a lower efficacy medication (adalimumab).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients who have previously been exposed to one or more advanced therapies, particularly tumor necrosis factor-α (TNF) antagonists, the AGA suggests using a higher efficacy medication (tofacitinib, upadacitinib, ustekinumab) or an intermediate efficacy medication (filgotinib, mirikizumab, risankizumab, guselkumab), rather than a lower efficacy medication (adalimumab, vedolizumab, ozanimod, etrasimod).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Infliximab has a possibly important benefit in achieving remission compared with adalimumab, mirikizumab, tofacitinib, and filgotinib with a low certainty of evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, there was no RCT for infliximab or golimumab in patients with prior exposure to biologics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lymphoma risk with TNF antagonists: AGA 2024 living guideline
“In a French population-based study, Lemaitre and colleagues estimated the annual incidence of lymphoma in patients treated with TNF antagonist monotherapy vs. unexposed patients to be 0.41 per 1000 person-years vs. 0.26 per 1000 person-years; after adjusting for potential confounders, the risk of lymphoma was 2.4-times higher in patients treated with TNF antagonist monotherapy25.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients exposed to combination therapy had six-fold increased risk of lymphoma, as compared to unexposed patients, and 2.3–2.5 times higher risk as compared to patients exposed to monotherapy with either agent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote